XRCC4 and cancer: Moreover, MEF2D binding activity to FANCD2, EXO1, and XRCC4 was significantly higher in cancer cells than in normal cells, and ARN3261 significantly reduced MEF2D binding activity to FANCD2, EXO1, and XRCC4 in cancer cells compared with normal cells (Supplemental Figure 5D).